Week In Review: Curon Bio Acquires Rights To Lymphoma Drug In $150 Million Deal

Curon Biopharma, a Shanghai clinical-stage in-licensing company, acquired China rights to Tenalisib, a dual PI3K delta and gamma inhibitor, from Rhizen Pharma. Rhizen will receive milestone payments worth up to $149.5 million, plus royalties.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.